Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, experts warn that prediction market platforms are exposing gaps in pharmaceutical vendor confidentiality agreements as outside partners gain early access to trial data, a pharma licensing roundup covers Roche’s deal for Rona Therapeutics’ ALK7-targeting RNAi candidate worth up to $1.06 billion in milestones and Pfizer’s collaboration with Enodia Therapeutics on Sec61 inhibitors valued at more than $500 million, and Pharmaceutical Executive speaks with PaxSafe’s Mark Talens on why waiting for perfect data is the biggest mistake pharma supply chains make.

Pharmaceutical Executive reports that prediction market platforms push pharma companies to rethink compliance and confidentiality among employees and outside partners alike. Experts say a CRO biostatistician can now review unblinded interim data months ahead of a sponsor’s topline readout, and closing that gap starts with rewriting confidentiality language in vendor contracts.

Two licensing deals close this week, as companies look to license differentiated platforms in metabolic disease and targeted protein degradation. Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, with up to $100 million in upfront and near-term payments and up to $1.06 billion in additional milestones. Separately, Pfizer partners with Enodia Therapeutics to discover Sec61 inhibitors in a deal valued at more than $500 million.

Finally, Pharmaceutical Executive speaks with PaxSafe chief commercial officer Mark Talens on why pharma supply chains struggle to capture AI’s benefits. Talens argues companies should stop waiting for perfect data, contending that information 60% to 70% accurate is often good enough to act on once it’s properly organized and contextualized. He pushes companies to build a data foundation first, rather than chasing whatever tool is trending.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.